Together these results suggest that small molecule inhibitors which block CARD14 activation of mTORC1 (e.g. PI 3-kinase, Akt or mTOR inhibitors) may have beneficial therapeutic effects in psoriasis in combination with an anti-inflammatory drug. Here, AKT1 is linked to psoriasis.